REGN Regeneron Pharmaceuticals Inc.

Regeneron Announces Investor Conference Presentations

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

  • BMO Biopharma Spotlight Series: Oncology at 9:30 a.m. ET on Wednesday, November 8, 2023
  • Truist Securities BioPharma Symposium at 3:20 p.m. ET on Wednesday, November 8, 2023
  • UBS Biopharma Conference at 11:00 a.m. ET on Thursday, November 9, 2023

  • Jefferies London Healthcare Conference at 2:30 p.m. GMT (9:30 a.m. ET) on Wednesday, November 15, 2023

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.

About Regeneron

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.

Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world. 

For additional information about Regeneron, please visit  or follow Regeneron on .

Contact Information:

Investor Relations

Ryan Crowe

914.847.8790



EN
25/10/2023

Underlying

REGNRegeneron Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Regeneron Pharmaceuticals Inc.

Free Trial
REGN Regeneron Pharm...

Regeneron Pharmaceuticals Inc: 2 directors

Two Directors at Regeneron Pharmaceuticals Inc sold/sold after exercising options 2,136 shares at between 778.516USD and 778.526USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary tr...

REGN REGENERON PHARMACEUTICALS INC.
02/11/26 February 11, 2026 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron Announces Investor Conference Presentations

Regeneron Announces Investor Conference Presentations TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference at 9:10 a.m. ET on Wednesday, March 4, 2026Leerink Partners 2026 Global Healthcare Conference at 10:40 a.m. ET on Wednesday, March 11, 2026 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days. About Regen...

February 11, 2026 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AA...

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy 36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies New Dupixent® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in children with atopic dermatitis TARRYTOWN, N.Y., Feb. 10, 2026 (GLOBE NEWSWIR...

February 10, 2026 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2...

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenes...

February 2, 2026 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Oper...

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024Fourth quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 34% to $4.9 billion versus fourth quarter 2024; full year 2025 Dupixent global net sales increased 26% to $17.8 billion versus 2024Fourth quarter 2025 EYLEA HD® U.S. net sales increased 66% to $506 million and total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.1 billion; fu...

January 30, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch